Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone

Endocrine-Related Cancer

Volumn 21, Issue 3, 2014, Pages 487-493

  Burgio, Salvatore Luca ^a   Conteduca, Vincenza ^a   Menna, Cecilia ^a   Carretta, Elisa ^a   Rossi, Lorena ^a   Bianchi, Emanuela ^a   Kopf, Barbara ^a   Fabbri, Francesca ^a   Amadori, Dino ^a   De Giorgi, Ugo ^a  

^a DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

Author keywords

Abiraterone; Bone flare; Castration resistant prostate cancer; CgA; Chromogranin A; CRPC; PSA

Indexed keywords

ABIRATERONE ACETATE; BIOLOGICAL MARKER; CHROMOGRANIN A; DOCETAXEL; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; ABIRATERONE; ANDROSTANE DERIVATIVE; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BONE METASTASIS; CANCER CHEMOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DISEASE COURSE; ELISA KIT; FOLLOW UP; GLEASON SCORE; HUMAN; KAPLAN MEIER METHOD; LIVER METASTASIS; LUNG EMBOLISM; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PREDICTION; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SERUM; THROMBOEMBOLISM; TREATMENT OUTCOME; UNIVARIATE ANALYSIS; VERY ELDERLY; ADENOCARCINOMA; BLOOD; BONE NEOPLASMS; CANCER STAGING; ENZYME LINKED IMMUNOSORBENT ASSAY; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SECONDARY; SURVIVAL RATE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANDROSTENOLS; BONE NEOPLASMS; CHROMOGRANIN A; ENZYME-LINKED IMMUNOSORBENT ASSAY; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84903585168     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-14-0071     Document Type: Article

References (25)

1. Angelsen A, Syversen U, Haugen OA, Stridsberg M, Mjølnerød OK & Waldum HL 1997 Neuroendocrine differentiation in carcinomas of the prostate: do neuroendocrine serum markers reflect immunohistochemical findings? Prostate 30 1-6. (doi:10.1002/(SICI) 1097-0045(19970101)30:1!1::AID-PROS1O3.0. CO;2-T)
2. Attard G, Reid AH, A'Hern R, Parker C, Oommen NB, Folkerd E, Messiou C, Molife LR, Maier G, Thompson E et al. 2009 Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. Journal of Clinical Oncology 27 3742-3748. (doi:10.1200/JCO. 2008.20.0642)
3. Berruti A, Dogliotti L, Mosca A, Bellina M, Mari M, Torta M, Tarabuzzi R, Bollito E, Fontana D & Angeli A 2000 Circulating neuroendocrine markers in patients with prostate carcinoma. Cancer 88 2590-2597. (doi:10.1002/1097- 0142(20000601)88:11!2590::AID-CNCR23O3.0.CO;2-D) (Pubitemid 30331968)
4. Berruti A, Mosca A, Tucci M, Terrone C, Torta M, Tarabuzzi R, Russo L, Cracco C, Bollito E, Scarpa RM et al. 2005 Independent prognosticrole of circulating chromogranin A in prostate cancer patients with hormone-refractory disease. Endocrine-Related Cancer 12 109-117. (doi:10.1677/erc.1.00876) (Pubitemid 40477092)
5. de Bono JS, Oudard S,OzgurogluM, Hansen S, Machiels JP, Kocak I, GravisG, Bodrogi I, MackenzieMJ, Shen L et al. 2010 Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376 1147-1154. (doi:10.1016/S0140-6736(10)61389-X)
6. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F et al. 2011 Abiraterone and increased survival in metastatic prostate cancer. New England Journal of Medicine 364 1995-2005. (doi:10.1056/NEJMoa1014618)
7. Burgio SL, Fabbri F, Seymour IJ, Zoli W, Amadori D & De Giorgi U 2012 Perspectives on mTOR inhibitors for castration-refractory prostate cancer. Current Cancer Drug Targets 12 940-949. (doi:10.2174/156800912803251234)
8. Burgio SL, Conteduca V, Ruttnas B, Carrozza F, Campedelli E, Bianchi E, Fabbri P, Montanari M, Carretta E, Menna C et al. 2014 PSA flare with abiraterone in patients with metastatic castration-refractory prostate cancer. Clinical Genitourinary Cancer [in press].
9. Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, Arora VK, Le C, Koutcher J, Scher H et al. 2011 Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 19 575-586. (doi:10.1016/j.ccr.2011.04.008)
10. Conteduca V, Aieta M, Amadori D & De Giorgi U 2014 Neuroendocrine differentiation in prostate cancer: current and emerging therapy strategies. Critical Reviews in Oncology/Hematology [in press].
11. Deftos LJ, Nakada S, Burton DW, di Sant'Agnese PA, Cockett AT & Abrahamsson PA 1996 Immunoassay and immunohistology studies of chromogranin A as a neuroendocrine marker in patients with carcinoma of the prostate. Urology 48 58-62. (doi:10.1016/S0090-4295(96)00089-1) (Pubitemid 26255959)
12. Fagerland MW & Hosmer DW 2013 A goodness-of-fit test for the proportional odds regression model. Statistics in Medicine 32 2235-2249. (doi:10.1002/sim.5645)
13. Fagerland MW, Hosmer DW& Bofin AM 2008 Multinomial goodness-of-fit tests for logistic regression models. Statistics in Medicine 27 4238-4253. (doi:10.1002/sim.3202)
14. Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, Staffurth JN, North S, Vogelzang NJ, Saad F et al. 2012 Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncology 13 983-992. (doi:10.1016/S1470-2045(12)70379-0)
15. Isshiki S, Akakura K, Komiya A, Suzuki H, Kamiya N & Ito H 2002 Chromogranin A concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer. Journal of Urology 167 512-515. (doi:10.1016/S0022-5347(01)69075-X)
16. Kalkner KM, Acosta S, Thorsson O, Frederiksen H, Nilsson A, Gustavsson B, Elingsbo M, Stridsberg M & Abrahamsson PA 2006 Octreotide scintigraphy and chromogranin A do not predict clinical response in patients with octreotide acetate-treated hormone-refractory prostate cancer. Prostate Cancer and Prostatic Diseases 9 92-98. (doi:10.1038/sj.pcan.4500843) (Pubitemid 43378876)
17. Kimura N, Hoshi S, Takahahi M, Takeha S, Shizawa S & Nagura H 1997 Plasma chromogranin A in prostatic carcinoma and neuroendocrine tumors. Journal of Urology 157 565-568. (doi:10.1016/S0022-5347(01)65203-0)
18. Matei DV, Renne G, Pimentel M, Sandri MT, Zorzino L, Botteri E, De Cicco C, Musi G, Brescia A, Mazzoleni F et al. 2012 Neuroendocrine differentiation in castration-resistant prostate cancer: a systematic diagnostic attempt. Clinical Genitourinary Cancer 10 164-173. (doi:10.1016/j.clgc.2011.12.004)
19. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M et al. 2004 Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. New England Journal of Medicine 351 1513-1520. (doi:10.1056/ NEJMoa041318) (Pubitemid 39315318)
20. Ryan CJ, Smith MR, de Bono JS,MolinaA, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S et al. 2013 Abiraterone in metastatic prostate cancer without previous chemotherapy. New England Journal of Medicine 368 138-148. (doi:10.1056/NEJMoa1209096)
21. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R et al. 2008 Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. Journal of Clinical Oncology 26 1148-1159. (doi:10.1200/JCO.2007. 12.4487)
22. Sciarra A, Di Silverio F, Autran AM, Salciccia S, Gentilucci A, Alfarone A & Gentile V 2009 Distribution of high chromogranin A serum levels in patients with nonmetastatic and metastatic prostate adenocarcinoma. Urologia Internationalis 82 147-151. (doi:10.1159/000200789)
23. Siegel R, Naishadham D & Jemal A 2013 Cancer statistics, 2013. CA: A Cancer Journal for Clinicians 63 11-30. (doi:10.3322/caac.21166)
24. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I et al. 2004 Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New England Journal of Medicine 351 1502-1512. (doi:10.1056/NEJMoa040720) (Pubitemid 39315317)
25. Taplin ME, George DJ, Halabi S, Sanford B, Febbo PG, Hennessy KT, Mihos CG, Vogelzang NJ, Small EJ & Kantoff PW 2005 Prognostic significance of plasma chromogranin A levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study. Urology 66 386-391. (doi:10.1016/j.urology.2005.03.040) (Pubitemid 41138103)